Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Children With Proteinuria
NCT07204743Active, not recruiting
- Sponsor
- Al-Quds University
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in chronic kidney disease (CKD), sponsored by Al-Quds University. Primary endpoints: Change in 24-hour proteinuria indexed to body surface area at 12 months and Change in estimated Glomerular Filtration Rate at 12 months. Started Aug 2025; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07204743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204743.